Intellia Therapeutics NTLA Stock
Intellia Therapeutics Price Chart
Intellia Therapeutics NTLA Financial and Trading Overview
| Intellia Therapeutics stock price | 12.62 USD |
| Previous Close | 10.21 USD |
| Open | 10.09 USD |
| Bid | 10.1 USD x 1100 |
| Ask | 10.15 USD x 1500 |
| Day's Range | 9.93 - 10.25 USD |
| 52 Week Range | 5.9 - 24.16 USD |
| Volume | 2.72M USD |
| Avg. Volume | 5.15M USD |
| Market Cap | 1.09B USD |
| Beta (5Y Monthly) | 2.315 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.69 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.54 USD |
NTLA Valuation Measures
| Enterprise Value | 738.95M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.8375679 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 20.562807 |
| Price/Book (mrq) | 1.4909439 |
| Enterprise Value/Revenue | 13.98 |
| Enterprise Value/EBITDA | -1.472 |
Trading Information
Intellia Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.315 |
| 52-Week Change | -55.60% |
| S&P500 52-Week Change | 14.81% |
| 52 Week High | 24.16 USD |
| 52 Week Low | 5.9 USD |
| 50-Day Moving Average | 10.93 USD |
| 200-Day Moving Average | 10.64 USD |
NTLA Share Statistics
| Avg. Volume (3 month) | 5.15M USD |
| Avg. Daily Volume (10-Days) | 5.1M USD |
| Shares Outstanding | 107.35M |
| Float | 102.02M |
| Short Ratio | 6.18 |
| % Held by Insiders | 4.79% |
| % Held by Institutions | 88.23% |
| Shares Short | 29.71M |
| Short % of Float | 31.35% |
| Short % of Shares Outstanding | 27.67% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | June 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -772.17% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.61% |
| Return on Equity (ttm) | -56.95% |
Income Statement
| Revenue (ttm) | 52.86M USD |
| Revenue Per Share (ttm) | 0.52 USD |
| Quarterly Revenue Growth (yoy) | 104.80% |
| Gross Profit (ttm) | -387246016 USD |
| EBITDA | -501873984 USD |
| Net Income Avi to Common (ttm) | -480193984 USD |
| Diluted EPS (ttm) | -4.69 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 459.65M USD |
| Total Cash Per Share (mrq) | 4.28 USD |
| Total Debt (mrq) | 102.59M USD |
| Total Debt/Equity (mrq) | 14.34 USD |
| Current Ratio (mrq) | 5.193 |
| Book Value Per Share (mrq) | 6.791 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -418584000 USD |
| Levered Free Cash Flow (ttm) | -177757504 USD |
Profile of Intellia Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 40 Erie Street |
| ZIP | 02139 |
| Phone | 857 285 6200 |
| Website | https://www.intelliatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 403 |
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Q&A For Intellia Therapeutics Stock
What is a current NTLA stock price?
Intellia Therapeutics NTLA stock price today per share is 12.62 USD.
How to purchase Intellia Therapeutics stock?
You can buy NTLA shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Intellia Therapeutics?
The stock symbol or ticker of Intellia Therapeutics is NTLA.
Which industry does the Intellia Therapeutics company belong to?
The Intellia Therapeutics industry is Biotechnology.
How many shares does Intellia Therapeutics have in circulation?
The max supply of Intellia Therapeutics shares is 107.35M.
What is Intellia Therapeutics Price to Earnings Ratio (PE Ratio)?
Intellia Therapeutics PE Ratio is now.
What was Intellia Therapeutics earnings per share over the trailing 12 months (TTM)?
Intellia Therapeutics EPS is -4.69 USD over the trailing 12 months.
Which sector does the Intellia Therapeutics company belong to?
The Intellia Therapeutics sector is Healthcare.
Intellia Therapeutics NTLA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| US Tech Global Market Composite NQGM | 2309.83 USD — |
+1.58
|
— — | 2282.44 USD — | 2312.75 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
| US Tech Biotechnology NBI | 5366.46 USD — |
+1.2
|
— — | 5276.16 USD — | 5372.71 USD — | — - | — — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
- {{ link.label }} {{link}}